BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

TipRanks11-22

BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485825131?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb","is_english":true,"pubTime":"2024-11-22 19:35","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485825131","market":"us","top_or_hot":-1,"title":"BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell","media":"TipRanks","content":"<div>\n<p>BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLRX","symbol_name":"BioLine Rx","start_time":0,"source_url":"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html","article_id":"2485825131","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485825131","pubTimestamp":1732275326,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Bioline RX Ltd Sponsored ADR  Q3 Earnings Cheat Sheet. BioLineRx’s Motixafortide Shows Promise in Sickle Cell","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLRX":"BioLine Rx","GMDA":"Gamida Cell Ltd.","BK4139":"生物科技"},"translate_title":"BioLineRx与Ayrmid通过Gamida Cell签订motixafortide许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMDA":1,"BLRX":0.9},"content_text":"BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization agent indicated in combination with filgrastim for collection and subsequent autologous transplantation in patients with multiple myeloma. Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda across all indications, excluding solid tumor indications, and in all territories other than Asia. BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for Aphexda in the Asia region. In exchange for the license, BioLineRx will receive a $10M upfront payment and is also eligible to receive up to an additional $87M of potential commercial milestones, plus royalties ranging from 18% to 23% on net sales of Aphexda. Ayrmid will add Aphexda to its commercial portfolio, which also includes Gamida Cell’s Omisirge, the first and only FDA-approved, nicotinamide, or NAM-modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. As part of this transaction, Ayrmid expects to transition certain members of BioLineRx’s U.S.-based commercial organization, who will support both stem cell transplant drugs. Through this transaction, BioLineRx will significantly reduce its long-term debt and operational expenses, which will be reviewed in detail during the company’s upcoming Q3 results conference call and webcast. BioLineRx also entered into a share purchase agreement for a $9M equity investment from certain funds managed by Highbridge Capital Management, LLC. This investment and the combined future potential commercial milestones from licensing agreements with Ayrmid and Gloria Biosciences, as well as royalties on net sales, are expected to provide a strong foundation for BioLineRx to advance its pipeline and identify potential additional assets for development. The equity investment is expected to close today, November 21, subject to the satisfaction of customary closing conditions. BioLineRx will continue the development of motixafortide for pancreatic ductal adenocarcinoma through meaningful collaborations, including an active Phase 2b PDAC study led by Columbia University, and supported equally by BioLineRx and Regeneron, as well as a planned Phase 2b PDAC study in China led by Gloria Biosciences.\n\nDon't Miss our Black Friday Offers:\n\nUnlock your investing potential with TipRanks Premium - Now At 40% OFF!\nMake smarter investments with weekly expert stock picks from the Smart Investor Newsletter\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee the top stocks recommended by analysts >>\n\n\nRead More on BLRX:\n\nBioLineRx Granted Extension to Meet Nasdaq Requirements\nBioline RX Ltd Sponsored ADR (BLRX) Q3 Earnings Cheat Sheet\nBioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials\nBioLineRx Secures Extended U.S. Patent for Motixafortide\nBioLineRx receives notification of allowance from USPTO for motixafortide","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485825131"}